Biopharma and healthcare CEOs are now the highest-paid group on the S&P 500, according to an annual study by the executive compensation consulting firm Equilar. And it’s biotech chiefs leading the way.
Regeneron CEO Leonard Schleifer–and his $47.4 million 2015 compensation–came in fourth on the list of 341 executives, according to data compiled by Equilar in conjunction with the Associated Press. Vertex Pharmaceuticals chief Jeffrey Leiden also ranked highly with his $28 million, as did Celgene’s Bob Hugin, now executive chairman at the company, who brought in $22.4 million last year.
Of course, some Big Pharma executives weren’t too far behind: Johnson & Johnson CEO Alex Gorsky was the fifth-highest-paid healthcare exec at $21.1 million, and Ken Frazier of Merck & Co. rated $19.9 million in 2015 compensation. Abbott Laboratories, which has sold off much of its pharma business but still maintains a drugs division, paid its CEO, Miles White, $19.4 million.
And John Martin, CEO at Gilead Sciences, also made the healthcare top 10 with $18.7 million, according to the International Business Times. In fact, only three companies in that top 10 were not drugmakers: CVS Health, Centene, and Universal Health Services.
The Equilar rankings line up alongside FiercePharma’s own CEO pay research, though the numbers themselves don’t exactly match because of differences in methodology. In some cases, our totals, taken from company proxy filings, are far higher.
According to our own rankings, biotech executives started shouldering into the ranks of the industry’s highest paid back in 2012, when Regeneron’s Schleifer topped the list at $30 million. Then, in 2013, biotech executives all but took over. Among the top 15 highest-paid drugmaker CEOs that year, 7 were biotech chiefs, with Schleifer, Hugin, and Martin among them.
For 2014, 9 of the 20 highest-paid executives led biotech companies, including Biogen’s George Scangos (at $18.63 million, by our count) and Alexion Pharmaceuticals CEO Leonard Bell, since retired, at $20.6 million.
The usual suspects ranked among the biggest earners for 2015, too, with Schleifer in second place with his $47.5 million, according to Regeneron’s latest proxy statement. Leiden ranked third at $45.8 million–an amount that proxy adviser ISS deemed “excessive” when the numbers went public last month.
But the highest-paid biopharma chief in 2015 was a complete newcomer with an outsized pay package. Horizon Pharma CEO Timothy Walbert brought in an unusually high amount–$93 million–but missed the Equilar list because his company isn’t part of the S&P 500.
By Tracy Staton
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
